STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
This study has been completed.
Information provided by:
Synta Pharmaceuticals Corp.
First received: July 20, 2004
Last updated: December 3, 2008
Last verified: December 2008
The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.
Metastatic or Unresectable Solid Tumors
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Phase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Male and female patients 18 years or older with one of the following malignancies:
- Histologically or cytologically confirmed hematological malignancy (other than Acute Myeloid Leukemia and Myelodysplastic Syndrome) and if treatment is medically indicated, or,
- Histologically-confirmed non-hematological malignancy that is metastatic or unresectable and for which no standard therapy is available.
- Patients with CLL, PLL, CML, CTCL, ATL, and Non-Hodgkin's Lymphoma may be entered if they are refractory to or have relapsed following conventional chemotherapy regimens such as alkylating agents (e.g. chlorambucil and cyclophosphamide), anthracycline combinations [e.g. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)], and/or purine analogues (e.g. fludarabine monophosphate and 2-CDA) and are not currently being considered for re-treatment with conventional regimens
- Patients with CLL and other leukemic malignancies will be staged according to the modified Rai staging criteria [low-risk, intermediate-risk and high risk]. All patients in the high-risk group (Stage III and IV) are eligible. Intermediate risk patients (Stage I and II) with one or more criteria of active disease (such as progressive lymphocytosis, lymphadenopathy, and splenomegaly, weight loss > 10% within 6 months, extreme fatigue, fever and/or night sweats without evidence of infection, etc.) are also eligible
- ECOG Performance Status of 0-2
- Life expectancy of greater than 12 weeks.
- Patients must have acceptable organ and marrow function at screening and pre-dose visits as defined below unless approved medically by the clinical investigator.
- Absolute neutrophils count greater than 1,000 cells/ul for patients with hematologic malignancies and ≥1,500 cells/ul for patients with solid tumors
- Platelets greater than 100,000/ul
- Hgb greater than 8.5 g/dL
- Total bilirubin must be <1.5 mg/dL or < 2X upper limit of normal
- AST (SGOT) < 2.5 times the upper limit of normal
- ALT (SGPT) < 2.5 times the upper limit of normal
- Adequate renal function (serum creatinine < 2.0 mg/dL or a calculated creatinine clearance greater than 50 mL/min)
- Electrocardiogram without evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator.
- NCI grade 0-1 left ventricular ejection fraction within 30 days of dosing.
- The effects of STA-5312 on the developing human fetus are unknown. Therefore, women of childbearing potential (defined as women under 50 years of age or history of amenorrhea for < 12 months prior to study entry) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform the treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent document.
- Women who are pregnant or lactating.
- Patients who have had chemotherapy, radiotherapy (except palliative radiation delivered to < 20% of bone marrow), immunotherapy, or corticosteroids ( > 10 mg/day of prednisone or equivalent) within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- The use of nitrosoureas or mitomycin C within 6 weeks prior to study entry.
- Patients with prior peripheral blood stem cell rescue or bone marrow transplantation.
- History of primary brain tumors or active brain metastases. (Patients with previously treated brain metastases who are not receiving corticosteroids or anticonvulsants may be considered for enrollment)
- History of stroke or other significant neurologic limitations within 6 months prior to study enrollment
- Use of any investigational agents within 4 weeks of study enrollment.
- History of severe allergic reactions to excipients (e.g. Tween 80) or had hypersensitivity reactions to other chemotherapeutic agents similar in structure to STA-5312.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, as determined by the investigator.
- History of active CNS-lymphoma, AIDS-related lymphoma, or any uncontrolled severe medical illness or infection.
- Grade 2 or higher sensory or motor neuropathy at screening.
- Major surgery (excluding that for diagnosis) within 4 weeks of enrollment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00088101
|Wilshire Oncology Medical Group
|Pamona, California, United States, 91767 |
|Baptist Cancer Institute
|Jacksonville, Florida, United States, 32207 |
|University of Chicago
|Chicago, Illinois, United States, 60637 |
|Tufts New England Medical Center
|Boston, Massachusetts, United States, 02111 |
|Newark Beth Israel Medical Center
|Newark, New Jersey, United States |
|Carolinas HealthCare System
|Charlotte, North Carolina, United States, 28203 |
|The West Clinic
|Memphis, Tennessee, United States, 38120 |
|The Sarah Cannon Cancer Center
|Nashville, Tennessee, United States, 37203 |
Synta Pharmaceuticals Corp.
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 20, 2004
||December 3, 2008
||United States: Food and Drug Administration
Keywords provided by Synta Pharmaceuticals Corp.:
Unresectable solid tumors
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 15, 2014
Neoplasms by Histologic Type
Immune System Diseases
Neoplasms by Site